Comparative effectiveness and safety of phototherapy, cytotoxic agents, and biologics in adults with atopic dermatitis: real-world multicenter cohort data - PubMed
2 days ago
- #Biologics
- #Phototherapy
- #Atopic Dermatitis
- Comparative effectiveness and safety of phototherapy, cytotoxic agents, and biologics in adults with atopic dermatitis (AD) was studied using real-world multicenter cohort data.
- The study included 1000 participants (200 per monotherapy group) across Saudi Arabia, comparing methotrexate (MTX), cyclosporine, narrowband ultraviolet B (NB-UVB) phototherapy, upadacitinib, and dupilumab.
- SCORAD (Scoring Atopic Dermatitis) was used to measure effectiveness at baseline and at weeks 2, 6, 12, and 24, with adjustments made for confounding factors using multinomial propensity scores.
- Dupilumab and upadacitinib showed the highest 24-week improvement in SCORAD (75.8% and 74.1% respectively), significantly better than other treatments.
- Upadacitinib had the highest adverse-event frequency (68.5%), while dupilumab had the lowest (9%).
- NB-UVB and methotrexate showed intermediate effectiveness, whereas cyclosporine had smaller sustained improvement.
- The study concludes that dupilumab and upadacitinib are associated with larger 24-week SCORAD improvements compared to conventional systemic therapies and NB-UVB, though results may be affected by residual confounding.